ARCHIVES

Kadcyla Extends Median PFS In Open-Label Phase III Trial

This article is from The Cancer Letter archive.

Vol. 36 No. 10 | October 25, 2013

Download PDF Visit The Full Archive

Related Articles

Clinton Budget Provides 4.7% Increase For NIH; $118 Million Raise for NCI

February 11, 1994

In Brief: Three Centers Win Comprehensive Designation; Hiatt Named Deputy Director, NCI Cancer Control

October 31, 1997

Dendritic Cell Vaccine Increases PFS in Phase II Clinical Trial

December 27, 2013

Oncologist Pans Breast Cancer Conference In Russian Heartland

August 19, 1994

AACR Journal Publishes a Henschke Letter Without Disclosure of Conflicts.

April 25, 2008

In Brief: NCI Gets $937 Million For FY 79 As Congress Adjourns; Cancer Act Renewed For Two Years

October 20, 1978